Immunoglobulin E specific for Phleum pratense allergen (Phl p-specific IgE) (Phl p-specific IgE)

Immunoglobulin E (IgE) antibodies specific for Phleum pratense (Timothy grass) allergens are the primary mediators of Timothy grass pollen allergy, a common cause of seasonal allergic rhinitis and asthma (StatPearls, 2023). These antibodies are produced by B cells upon exposure to Timothy grass allergens such as Phl p 1 and Phl p 5 (WHO/IUIS, 2024). Once produced, they bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to the pollen, the allergens cross-link the bound IgE, triggering the release of inflammatory mediators like histamine and leukotrienes (PubMed, 2023). Therapeutic strategies involve neutralizing IgE with monoclonal antibodies like Omalizumab or inducing immunological tolerance through allergen-specific immunotherapy (AIT) (Durham & Shamji, 2023). Monitoring levels of these specific antibodies is crucial for diagnosis and assessing the efficacy of treatment. Anti-IgE therapy specifically targets the Fc region of the IgE molecule to prevent receptor binding, while AIT aims to reduce the ratio of specific IgE to IgG4 (NCBI, 2023).

Other names

Timothy grass-specific IgEAnti-Phleum pratense IgEsIgE Phl pPhleum pratense-specific IgEAnti-Phl p IgE

Anti-IgE therapy (e.g., Omalizumab) works by binding to the Cε3 domain of the IgE molecule, which is the site of interaction with the high-affinity IgE receptor (FcεRI), thereby preventing IgE from sensitizing mast cells and basophils (NCBI, 2023). Allergen-specific immunotherapy (AIT) involves the administration of increasing doses of Phleum pratense allergens to induce immune deviation from a Th2 to a Th1/Treg response, leading to the production of IgG4 blocking antibodies that intercept allergens before they can bind to IgE on effector cells (Durham & Shamji, 2023).